Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02403843 · ClinicalTrials.gov registry record
RNS® System Epilepsy Post-Approval Study
A clinical trial of Epilepsy, sponsored by NeuroPace.
- Active
- Registry status
- 375
- Enrollment target
- 20
- Study locations
NCT02403843: Active study of Epilepsy, sponsored by NeuroPace.
NCT02403843 is a study of Epilepsy that is active but no longer recruiting, run by NeuroPace. The registered enrollment target is 375 participants, below the 950-participant average among 160 other Epilepsy trials with a reported enrollment target (61% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02403843, a study of Epilepsy, is active but no longer recruiting, sponsored by NeuroPace.
- ACTIVE NOT RECRUITING
- Registry status
- 375 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to follow patients with partial onset seizures prospectively over 5 years in the real-world environment to gather data on the long-term safety and effectiveness of the RNS System at qualified CECs by qualified neurologists, epileptologists, and neurosurgeons trained on the RNS System.
Primary Outcome
Calculate annual SAE rates over time in the entire subject population as well as within subpopulations.
Conditions Studied
Interventions
- DEVICE RNS System
Study Locations (20)
California
- University of California, Irvine - Irvine
- University of Southern California - Los Angeles
- University of California, Los Angeles - Los Angeles
- Stanford University - Palo Alto
- University of California, San Francisco - San Francisco
Kentucky
- University of Kentucky - Lexington
- Norton Neuroscience Institute - Louisville
Alabama
- University of Alabama, Birmingham - Birmingham
Colorado
- University of Colorado Denver - Aurora
Connecticut
- Yale University - New Haven
Florida
- University of South Florida - Tampa
Georgia
- Emory University - Atlanta
Illinois
- Rush University Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 375 participants |
| Start Date | 2015-06 |
| Est. Completion | 2026-01 |
What the registry record for NCT02403843 still lists
NCT02403843 is an observational study that tracks outcomes without assigning an intervention. The registered 375 participants enrollment target is mid-sized for trials with a published cap, below the 950-participant average among 160 other Epilepsy trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which RNS System is the first listed.
NCT02403843 names 20 study sites across 15 states, led by California, Kentucky, Alabama.
Frequently Asked Questions
What is clinical trial NCT02403843 about?
NCT02403843 is a clinical study titled "RNS® System Epilepsy Post-Approval Study". The purpose of the study is to follow patients with partial onset seizures prospectively over 5 years in the real-world environment to gather data on the long-term safety and effectiveness of the RNS System at qualified CECs by qualified neurologists, epileptologists, and neurosurgeons trained on th...
What is the current status of trial NCT02403843?
This trial is currently active not recruiting. The enrollment target is 375 participants. The study started on 2015-06. Estimated completion is 2026-01.
What conditions does trial NCT02403843 study?
This clinical trial studies the following conditions: Epilepsy.
What interventions are being tested in trial NCT02403843?
The interventions under investigation include: RNS System (DEVICE).
Who is sponsoring clinical trial NCT02403843?
This trial is sponsored by NeuroPace, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02403843 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02403843's enrollment target sits among peer trials
375 17th of 160 higher than 144 of 160 other Epilepsy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Retrospective Survey-based Multicenter Study to Delineate the Molecular and Phenotypic Spectrum of Epilepsy-dyskinesia Syndromes
RECRUITING
-
Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up
RECRUITING
-
SeizEAR Safety Study
RECRUITING · NA
-
Physiological-based Pharmacokinetics Approach to Medication Exposure During Pregnancy and Breastfeeding
RECRUITING
-
Tumor Related Epilepsy
RECRUITING
-
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03686124 · 375 participants · Phase 1
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- NCT04059172 · 375 participants · Early Phase 1
Efficacy of Combined Ibuprofen and Acetaminophen Therapy Versus Ibuprofen Alone Versus Placebo Alone for Pain Management
- NCT04134923 · 375 participants
Imaging Biomarkers in Preclinical and Symptomatic AD
- NCT04569747 · 375 participants · Phase 2
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia